Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer

Justin F. Gainor, Leila Dardaei, Satoshi Yoda, +30

Cancer Discovery

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

Luc Friboulet, Nanxin Li, Ryohei Katayama, +21

Cancer Discovery

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Adam Crystal, Alice T. Shaw, Lecia V. Sequist, +23

Science

Resensitization to Crizotinib by the Lorlatinib<i>ALK</i>Resistance Mutation L1198F

Alice T. Shaw, Luc Friboulet, Ignaty Leshchiner, +20

New England Journal of Medicine

Oncogenic AgentMedicineGeneticsPharmacologyMolecular Biology +13

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Helen Y. Zou, Luc Friboulet, David P. Kodack, +30

Cancer Cell

Drug TargetHealth SciencesPreclinical ModelsMedicineRational Drug Design +8

Acquired Resistance to Crizotinib from a Mutation in <i>CD74</i>–<i>ROS1</i>

Mark M. Awad, Ryohei Katayama, Michele McTigue, +19

New England Journal of Medicine

Genome InstabilitySame Resistance MutationOncogenic AgentMedicineGenetics +12

ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer

Luc Friboulet, Ken A. Olaussen, Jean‐Pierre Pignon, +25

New England Journal of Medicine

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer

Satoshi Yoda, Michael S. Lawrence, Benjamin J. Burke, +21

Cancer Discovery

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

Ryohei Katayama, Luc Friboulet, Sumie Koike, +10

Clinical Cancer Research

Clinicogenomic Analysis of <i>FGFR2</i> -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

Ian M. Silverman, Antoine Hollebecque, Luc Friboulet, +7

Cancer Discovery